Ascendis Pharma A/S
ASND
219 hedge funds and large institutions have $9.31B invested in Ascendis Pharma A/S in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 79 increasing their positions, 69 reducing their positions, and 25 closing their positions.
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
14% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 69
13% more capital invested
Capital invested by funds: $8.28B → $9.31B (+$1.04B)
8% more funds holding
Funds holding: 203 → 219 (+16)
0% more funds holding in top 10
Funds holding in top 10: 17 → 17 (0)
1.23% less ownership
Funds ownership: 105.16% → 103.93% (-1.2%)
33% less call options, than puts
Call options by funds: $39.3M | Put options by funds: $58.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$234M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$107M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$94.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$66.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$182M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$100M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$90.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$84.4M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$67.5M |
ASND Hedge Fund Activity: Q3 2024 in Review
219 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2024, worth a combined $9.31B — up 13% from $8.28B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ASND positions and 25 closed out — a net gain of 17 holders — while 79 added to existing stakes and 69 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $234M. The largest seller was Wellington Management Group, cutting an estimated $182M.
- 219 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2024, up from 203 in Q2 2024.
- Funds reported $9.31B of Ascendis Pharma A/S stock for Q3 2024, up 13% quarter-over-quarter.
- 42 funds opened new Ascendis Pharma A/S positions in Q3 2024 and 25 closed out, a net change of +17 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $234M added.
- The largest Ascendis Pharma A/S seller in Q3 2024 was Wellington Management Group, an estimated $182M sold.
Based on aggregated 13F filings for Q3 2024.